Last reviewed · How we verify
Extended-release carbamazepine
At a glance
| Generic name | Extended-release carbamazepine |
|---|---|
| Sponsor | Validus Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants (PHASE1)
- A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Zongertinib in the Blood (PHASE1)
- A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012) (PHASE1)
- A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012) (PHASE1)
- Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020) (PHASE1)
- Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants (PHASE1)
- Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency (PHASE2)
- Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extended-release carbamazepine CI brief — competitive landscape report
- Extended-release carbamazepine updates RSS · CI watch RSS
- Validus Pharmaceuticals portfolio CI